Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting
November 01, 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO
September 28, 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 28, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology
September 21, 2017 16:15 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
September 11, 2017 03:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer
July 05, 2017 07:00 ET
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology...
BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer
June 29, 2017 05:10 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 29, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and...
BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting
June 05, 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
April 21, 2017 07:00 ET
|
BeiGene, LTD.
BEIJING, April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of...
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
April 21, 2017 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
December 30, 2016 09:00 ET
|
BeiGene, LTD.
BEIJING, Dec. 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of...